Checkpoint inhibitors can only amplify an antitumor immune response that already exists, which is why immunologically “cold” ...

Looking to invest in biotech stocks? Learn what they are, explore top options, and find out how to get started in this ...

This Week's Global Pharma News] Roche and Pfizer Receive US FDA Approvals, argenx Discontinues Phase 3 Trial, New ...

SHELTON, CT / ACCESS Newswire / October 5, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical ...

Researchers at Visva-Bharati University have introduced the AI-modulated Pólya urn, a stochastic framework that unifies ...

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to ...

This is Minehisa from MISORAE."Someone who has done various things while committing to management issues, and as a result, has accumulated the perspective and experience of a management member."This i ...

AI-enabled digital pathology analysis shows aglatimagene significantly increased lymphocyte infiltration and immune engagement with tumor cells compared to standard-of-care radiotherapy alone two ...

Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung ...

Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these ...

Replimune Group, Inc. announced that TUDRIQEV? (vusolimogene oderparepvec-wtpg) is now commercially available in the United States. TUDRIQEV is indicated in combination with nivolumab for the ...

RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic therapy Phase 3 ...